Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times

Gayathri T Selvarajah*, Jolle Kirpensteijn, Monique E van Wolferen, Nagesha AS Rao, Hille Fieten and Jan A Mol

Address: 1Department of Clinical Sciences of Companion Animals, Utrecht University, Yalelaan 108, 3584 CM Utrecht, The Netherlands and 2Department of Veterinary Clinical Studies, University Putra Malaysia, 43400 UPM Serdang, Malaysia

Email: Gayathri T Selvarajah* - G.T.Selvarajah@uu.nl; Jolle Kirpensteijn - J.Kirpensteijn@uu.nl; Monique E van Wolferen - M.E.vanWolferen@uu.nl; Nagesha AS Rao - nagesha_nrao@yahoo.com; Hille Fieten - H.Fieten@uu.nl; Jan A Mol - J.A.Mol@uu.nl

* Corresponding author

Abstract

Background: Gene expression profiling of spontaneous tumors in the dog offers a unique translational opportunity to identify prognostic biomarkers and signaling pathways that are common to both canine and human. Osteosarcoma (OS) accounts for approximately 80% of all malignant bone tumors in the dog. Canine OS are highly comparable with their human counterpart with respect to histology, high metastatic rate and poor long-term survival. This study investigates the prognostic gene profile among thirty-two primary canine OS using canine specific cDNA microarrays representing 20,313 genes to identify genes and cellular signaling pathways associated with survival. This, the first report of its kind in dogs with OS, also demonstrates the advantages of cross-species comparison with human OS.

Results: The 32 tumors were classified into two prognostic groups based on survival time (ST). They were defined as short survivors (dogs with poor prognosis: surviving fewer than 6 months) and long survivors (dogs with better prognosis: surviving 6 months or longer). Fifty-one transcripts were found to be differentially expressed, with common upregulation of these genes in the short survivors. The overexpressed genes in short survivors are associated with possible roles in proliferation, drug resistance or metastasis. Several deregulated pathways identified in the present study, including Wnt signaling, Integrin signaling and Chemokine/cytokine signaling are comparable to the pathway analysis conducted on human OS gene profiles, emphasizing the value of the dog as an excellent model for humans.

Conclusion: A molecular-based method for discrimination of outcome for short and long survivors is useful for future prognostic stratification at initial diagnosis, where genes and pathways associated with cell cycle/proliferation, drug resistance and metastasis could be potential targets for diagnosis and therapy. The similarities between human and canine OS makes the dog a suitable pre-clinical model for future 'novel' therapeutic approaches where the current research has provided new insights on prognostic genes, molecular pathways and mechanisms involved in OS pathogenesis and disease progression.
Background

Naturally occurring cancer in the dog has been repeatedly emphasized as an excellent model for humans, because similarities in histology, tumor biology, disease progression and response to conventional therapies offer a unique translational opportunity in the broader prospect of cancer research. Since the release of the canine genome in 2005, dog spontaneous tumors have been in the spotlight for ‘state-of-the-art’ linkage to preclinical human cancer research, where strong similarities in cancer associated gene families were found when comparing the humans to dog [1]. Among the tumors of the dog, osteosarcoma (OS), an aggressive malignant bone tumor that occurs spontaneously, is one of the most outspoken and invaluable cancer for comparative oncology studies [2]. Commonly affected dog breeds include the large-to-giant breeds [3-6]. The median age of dogs affected with OS is around 7 to 10 years, with a subset of tumors arising in younger dogs (18-24 months). The appendicular skeleton is affected in 77% of the dogs, implying an association with rapid early bone growth [3,7] as well as with increased stress on weight bearing areas of the limb. Affected dogs often present with progressive lameness, hard bony swelling or even pathological fracture of the affected bone [8,9]. No strong sex predilection is noted, although males are overrepresented in most studies. Histologically, OS is a heterogeneous tumor that in addition to producing an osteoid matrix, can also present with a fibroblastic and cartilaginous matrix. OS is commonly subdivided into osteoblastic, fibroblastic, telangiectatic, chondroblastic and mixed forms classifications [10].

The prognosis of dogs with OS is unfortunately poor, mainly due to its fast spreading nature; by the time the tumor is found at the primary site, most have already metastasized [11], usually to the lungs, or less frequently in bone and other soft tissues [12]. The goal of therapy is to remove the primary tumor and detectable metastases as well as to initiate multimodal chemotherapy to eradicate micrometastases. The prognosis varies with the type of surgery and chemotherapy [13,14]. The prognosis for dogs without surgery and adjuvant chemotherapy is poor, with a median survival time of 1-3 months. With amputation alone, median survival time can vary from 1 to 6 months [12,15,16]. Some dogs develop metastases within 4 months regardless of the therapy modality, while others survive for longer periods of time [17]. One of the key factors contributing to intensified proliferative activity of the tumor in dogs leading to poor outcome is the deregulation of cellular signals, including growth factors and hormones [18,19]. This poor prognosis feature is comparable to human OS, where there is still ample room for new therapeutics development, primarily to eradicate micrometastases and improve survival.

Recent advances in human cancer management have focused on molecular targeted therapies where high throughput screening technologies have been incorporated to identify novel markers for cancer pathogenesis and specific characterizations of tumors. Over the last decade, gene expression profiling has been able to identify key genes and cellular signaling pathways involved in development and progression of human OS. Microarray technology, a robust method for analyzing global gene expression profiles has been incorporated in those studies. In line with this technology, human OS cell lines have been compared with normal human osteoblasts to provide insights into genes that are involved in OS tumorigenesis [20]. Aside from the conventional comparisons between tumor and normal tissues, other comparisons have been conducted in human OS, including the differential analysis of metastatic tumors compared with less aggressive tumor models [21], gene expression profiling that predicts response to chemotherapy [22] and molecular classification of chemotherapy resistant pediatric OS [23]. The use of these genetic markers for diagnosis and/or prognosis in canine OS is not completely understood and to date no such prognostic global gene profiling have been carried out for the dog.

Thus, for comparative pathobiology and new drug discovery arenas, it would be useful to stratify dogs at diagnosis into ‘poor’ and ‘good’ outcome groups based on tumor gene expression profiles. To address this issue, a canine-specific cDNA microarray representing 20,313 genes was used to differentiate the gene expression profile of tumors from dogs that survived less than 6 months from the profiles of those that survived longer. The survival-associated genes and cellular signaling pathways based on global gene expression profiles of thirty-two primary canine OS are identified. Molecular profiling of canine OS with known survival times will help define tumor biology pertaining to prognosis and facilitate future targeted therapies.

Results

Retrospective clinical - histological data analysis

The 32 dogs in this study varied in clinicopathological parameters (Table 1). The present experimental design hereby defines dogs with poor prognosis (short survivors, SS) as those surviving less than 6 months and favorable prognosis (long survivors, LS) as those dogs with survival of 6 months or longer. The overall survival times (ST) of these dogs were between 6 and 1752 days with a median value of 204 days. Dogs with poor prognosis (SS) had a ST of 6-169 days (<6 months); while the better prognosis group (LS) had a ST of 239-1752 days (>6 months). Beside the distinction in survival time between these two groups, the SS group also exhibited a significantly shorter disease free interval in a Kaplan-Meier survival analysis.
## Table 1: Summary of clinical and histology data from 32 dogs used in this study

| SURVIVAL GROUP | ARRAY | SURVIVAL TIME (days) | AGE (Year, Month) | SEX | BREED | TUMOR LOCATION | HISTOLOGY SUBTYPE | HISTOLOGY GRADE | POST OPERATIVE CHEMOTHERAPY |
|----------------|-------|----------------------|-------------------|-----|-------|----------------|-------------------|----------------|-----------------------------|
| SHORT 1        | 1     | 36                   | 9.2               | F   | Boxer | Rib            | OB/CB/FB          | highly malignant | No                          |
| SHORT 2        | 2     | 79                   | 8.8               | M   | Vizsla| distal radius  | OB                | highly malignant | Yes                         |
| SHORT 3        | 3     | 13                   | 2.6               | F   | Labrador retriever | proximal humerus | OB                | highly malignant | No                          |
| SHORT 4        | 4     | 169                  | 4.8               | M   | Great Dane | distal radius | OB/FB             | highly malignant | Yes                         |
| SHORT 5        | 5     | 121                  | 7.9               | M   | Rottweiler| proximal humerus | OB/CB/FB         | medium malignant | Yes                         |
| SHORT 6        | 6     | 66                   | 9.8               | M   | Dobermann| ulna           | OB/TL             | medium malignant | No                          |
| SHORT 7        | 7     | 119                  | 7.1               | F   | Rottweiler| distal femur  | OB                | highly malignant | Yes                         |
| SHORT 8        | 8     | 66                   | 11.6              | F   | Belgian Shepherd (tervuren) | proximal humerus | OB      | highly malignant | Yes                         |
| SHORT 9        | 9     | 77                   | 7.0               | M   | Great Dane | distal tibia | OB/FB             | highly malignant | Yes                         |
| SHORT 10       | 10    | 164                  | 6.7               | M   | Dobermann| distal tibia  | CB                | highly malignant | No                          |
| SHORT 11       | 11    | 140                  | 7.4               | M   | Rottweiler| distal radius & ulna | OB/FB         | highly malignant | No                          |
| SHORT 12       | 12    | 61                   | 5.8               | F   | Great Dane | distal femur  | OB                | medium malignant | Yes                         |
| SHORT 13       | 13    | 50                   | 11.9              | M   | Belgian Shepherd (tervuren) | distal tibia & fibula | OB      | highly malignant | No                          |
| SHORT 14       | 14    | 47                   | 6.8               | F   | Rhodesian ridgeback | distal femur | OB/FB             | highly malignant | Yes                         |
| SHORT 15       | 15    | 65                   | 6.2               | M   | Great Dane | proximal humerus | OB/CB             | highly malignant | Yes                         |
| SHORT 16       | 16    | 6                    | 6.1               | F   | Rottweiler| mandible     | OB/FB             | highly malignant | No                          |
| LONG 17        | 17    | 352                  | 9.8               | M   | Dobermann| proximal tibia | OB/FB             | medium malignant | Yes                         |
| LONG 18        | 18    | 274                  | 8.8               | M   | cross | ulna          | OB/FB/TL          | medium malignant | Yes                         |
| LONG 19        | 19    | 1752                 | 3.8               | M   | Stabyhoun| extraskeletal | OB/FB             | highly malignant | Yes                         |
| LONG 20        | 20    | 307                  | 4.3               | M   | Great Dane | distal radius | CB                | medium malignant | Yes                         |
| LONG 21        | 21    | 1619                 | 3.7               | F   | Siberian husky | mandible      | OB/TL             | highly malignant | No                          |
| LONG 22        | 22    | 1185                 | 2.3               | F   | Flatcoat retriever | rib       | OB/TL             | highly malignant | No                          |
| LONG 23        | 23    | 1289                 | 5.0               | F   | Rottweiler| distal radius | OB/FB             | highly malignant | Yes                         |
| LONG 24        | 24    | 257                  | 8.4               | F   | Bouvier | distal radius | OB/FB             | highly malignant | Yes                         |
| LONG 25        | 25    | 445                  | 10.4              | M   | Scottish collie | distal radius | OB        | highly malignant | Yes                         |
| LONG 26        | 26    | 284                  | 7.0               | F   | cross | distal radius | OB/CB             | highly malignant | Yes                         |
| LONG 27        | 27    | 239                  | 8.4               | M   | Rottweiler| scapula      | OB/FB             | highly malignant | Yes                         |
| LONG 28        | 28    | 705                  | 8.3               | F   | cross | metatarsus    | FB                | low malignant    | Yes                         |
| LONG 29        | 29    | 348                  | 9.0               | F   | Mastiff | distal radius | OB                | highly malignant | Yes                         |
| LONG 30        | 30    | 312                  | 5.8               | M   | Mastiff | scapula      | OB/FB             | highly malignant | Yes                         |
| LONG 31        | 31    | 920                  | 7.3               | M   | Belgian Shepherd (malinois) | mandible | OB/FB/CB      | highly malignant | No                          |
| LONG 32        | 32    | 312                  | 10.2              | M   | Rottweiler| distal femur | OB/CB             | highly malignant | Yes                         |

**Abbreviations:** M, male; F, female; OB, osteoblastic; CB, chondroblastic; FB, fibroblastic; TL, telangiectic; highly malignant, Grade 3; medium malignant, Grade 2; low malignant, Grade 1.
(Figure 1). Fisher’s exact test revealed no significant differences in discrete data distribution between the 2 groups of survival with respect to sex, neuter status, histological grade and postoperative chemotherapy, the exception being metastatic disease status (P < 0.018). This is because metastatic disease was seen in all dogs in the short survivor’s group while 6 dogs from the long survivors’ group did not develop metastasis before death (died due to other causes); this was censored for subsequent analyses (Table 2). Tumors were located mostly at appendicular sites, but other locations such as mandible, rib, scapula, metatarsus and extraskeletal were also present. Further potential confounders identified through a univariable Cox regression analysis of the whole population (n = 32) included histological grade, postoperative chemotherapy, alkaline phosphatase (ALP) measurement at diagnosis, sex, age and neuter status (Additional file 1). Alkaline phosphatase (ALP) level and age at presentation were found to have P values of less than 0.15 and were then further subjected to multivariate analysis. Elevation of serum ALP is a known negative prognosticator in dogs with OS and this is apparently also true here, multivariate analysis using the ALP data available for the dogs in this study (n = 23) showed this confounder to be significantly associated with survival (HR = 1.005; CI: 1.000-1.009 with corresponding P value of 0.035).

Although the small population size in the present study is unlikely to show significant differences, it is important to identify any possible confounding factors that may influence survival/prognosis and should be considered when interpreting the expression data at biological levels. In both survival groups, dogs were subjected to a variety of single agent therapies, including lobaplatin, doxorubicin or carboplatin; or a combination of carboplatin and doxorubicin. Some were treated with postoperative chemotherapy and some not, and Kaplan-Meier analysis showed that chemotherapy did not significantly prolong survival in the overall population (log rank score 1.353, P value 0.245), neither among short survivors (log rank score 0.460, P value of 0.498) nor among long survivors (log rank score 0.033, P value 0.857) separately (Figure 2). Although these survival curves only represent bivariable analyses (treated vs. not treated) that do not include all confounding variables, a separate univariable and subsequent multivariable statistical model with inclusion of variables such as histological grade, alkaline phosphatase, neuter status, gender and age upon chemotherapy stratification revealed that none of the variables appeared to have influenced survival significantly (Additional file 2). An additional important insight from the long survival group is that all 4 dogs that were censored from the study (death due to other causes and no apparent metastatic disease until death) received postoperative chemotherapy, which suggests possibilities that these dogs had responded reasonably well to the chemotherapeutic regime. Finally, since both survival groups consist of comparable heterogeneous populations of dogs and poor survivors tend to have higher ALP measurements, the arbitrary but defendable approach to a binary distinction of ‘good’ and ‘poor’ outcome based on 6 month survival time is supported for further gene expression profiling.

Microarray data analysis

Comparison of short and long survivors using two-class unpaired Significance Analysis of Microarrays (SAM)

Table 2: Distribution of variables between the SS and LS groups by Fisher’s exact test

| Parameter                              | Short survivors | Long survivors | (Fisher’s exact test) P value |
|----------------------------------------|-----------------|----------------|-------------------------------|
|                                        | n               | n              |                               |
| Gender                                 |                 |                |                               |
| Male                                   | 9               | 9              | > 0.999                       |
| Female                                 | 7               | 7              |                               |
| Neutered status                        |                 |                |                               |
| Neutered                               | 5               | 6              | > 0.999                       |
| Intact                                 | 11              | 10             |                               |
| Metastasis present at time of death    |                 |                | 0.018**                      |
| Yes                                    | 16              | 10             |                               |
| No                                     | 0               | 6              |                               |
| Postoperative chemotherapy             |                 |                |                               |
| No                                     | 7               | 4              | 0.458                        |
| Yes                                    | 9               | 12             |                               |
| Histological grade                    |                 |                |                               |
| Low and medium                         | 3               | 4              | > 0.999                       |
| High                                   | 13              | 12             |                               |

Analysis on discrete variables comparing the short and long survivors revealed no significant differences in the distribution of variables assessed except for metastatic disease status. **Significance defined as P < 0.05.
revealed fifty-one genes that were differentially regulated at a false discovery rate (FDR) of 10%. All these genes were found to be upregulated in the SS group where 37 of them were upregulated with a fold change of more than 1.4 (Table 3). Of the 37 genes, 8 were not functionally annotated for the dog and 5 others were unknown Expressed Sequence Tags (ESTs). To further visualize the gene expression data, hierarchical clustering was performed on all 32 arrays based on the differentially expressed genes (Figure 3). A gene tree dendrogram revealed two distinct clusters, where Cluster 2 appears to distinguish long from short survivors or, in other words, this signature defines prognosis based on the 6 month survival binary outcome. Within Cluster 1, particular attention should also be given to a further separation into 2 different subgroups (A and B). Although Fisher’s exact test revealed no significant differences among the variables assessed with respect to histological grade, sex, neuter status and postoperative chemotherapy (Additional file 3), this could primarily be due to the low number of subjects within each subgroup (n = 8) which most likely will not allow statistical significance. We did find a significant difference in terms of overall survival time between the two subgroups, with subgroup A: having a shorter survival time than subgroup B. The log rank score was 5.82, with a corresponding P value of 0.0158 (Figure 4).

Quantitative real-time PCR analysis
To verify the microarray analysis, QPCR was performed on four candidate genes and two reference genes, HPRT and RPS19 that were used to normalize the expression data. The overall expression patterns of the candidate genes were comparable to the microarray analysis. Quantitative real-time PCR revealed common overexpression of ANKRD17, MGST1, MRPS31 and NCOR1 in short survivors compared to long survivors by 1.35, 1.46, 1.53 and 1.1 fold respectively.

Molecular functions and biological process analyses
Various molecular functions of the genes differentially expressed by short and long survivors of canine OS were defined into categories according to the Gene Ontology database, including: DNA repair and integrity, cell cycle/ proliferation, stress response, apoptosis regulation, protein modification and metabolism, and mRNA transcription regulation (Additional file 4). Several of these genes have been implicated in tumorigenesis and cancer biology for both humans and dogs. HSP70/MOT, HSP60 and
NCOR1 have been implicated in human OS, while HMG1, HSP90 and MGST1 have been associated with both human and canine OS. Generally, the overexpressed genes were linked to 3 main biological processes known in advanced cancer: mainly cell cycle and proliferation, followed by drug resistance and/or metastasis (Table 4).

Pathway analyses
The number of annotated genes in the present study is too low to form any relevant protein networks. Therefore, we used the ‘Shortest path analyses’ by MetaCore, which allows for one intermediate gene to be linked to the differential genes in order to form a more informative gene-protein network. These intermediate genes may be a transcription factor, receptor or ligand. Transcripts with limited information available on network or associated with a pathway were excluded, leaving a final gene regulatory network generated based on 11 genes that were overexpressed in short survivors of canine OS with the addition of seven transcription factors, one receptor and a ligand (Figure 5). Transcription factors p53, c-myc, SP1 and NF-kB seemed to play roles as ‘central hubs’ connecting these transcripts. All three heat shock proteins (HSP90-alpha, HSP60 and MORT/HSAP9/GRP75) appeared to be linked to a common transcription factor c-myc.

Because the interaction among genes is definitely more complex, we performed a PANTHER® pathway analysis in which functional and pathway data available on human transcripts were used as reference to analyze the transcripts from the present study in the dog. PANTHER® analysis on the 51 differentially expressed genes by SAM yields too few genes associated with a cellular signaling pathway, undermining the power of pathway analysis. This is mainly because a majority of genes are not associated with a signaling pathway, but also because the dog lacks functional annotation at present. Therefore, we excluded the FDR correction for multiple testing and selected a longer list of genes with a threshold of P < 0.05 from EDGE (a microarray analyzing software). After removal of non-annotated genes and transcript replicates, there were 533 genes mapped on PANTHER® which permitted further analysis. Identified pathways included the top four commonly associated with cancer and OS pathogenesis: Wnt signaling, inflammation mediated by chemokine and cytokine signaling, integrin signaling, and ubiquitin proteasome (Table 5). Our pathway list was then compared with three microarray datasets of human osteosarcoma [24,25]. Two gene lists were obtained from Srivastava A., et al., 2006: one of genes overexpressed in human osteogenic sarcomas in comparison to normal bones, the other a partial list of genes upregulated in a highly metastatic human OS cell line, and a gene list from Rajkumar T., et al., 2008 identifying genes that were differentially expressed in a doxorubicin drug resistant human OS cell line. These gene lists, obtained either from the authors themselves or via the supplementary tables provided in their articles, were subsequently subjected to PANTHER® pathway analysis as similarly conducted in the present study to define pathways pertaining to drug resistance/metastasis/tumorigenesis of OS. Comparison of the top...
20 pathway hits from these 3 studies in human OS (Table 5) revealed seven pathways overlapping with the present study on canine OS, including Wnt, chemokine/cytokine, Alzheimer disease-presenilin pathway, fibroblast growth factor (FGF), platelet derived growth factor (PDGF), apoptosis and interleukin signaling pathways.

Discussion
Canine OS gene expression profiling as a model for human OS
Osteosarcoma (OS) is a devastating disease in both human and dogs. The clinical presentation, characteristics and disease progression is similar in people and dogs except for the age of clinical onset, where 75% of human cases affect young adolescents while onset is predominantly observed in middle-aged to older dogs. For dogs, the decision to initiate treatment is often made by the owners. The standard therapy for canine OS primarily involves amputation or limb sparing surgery, followed by adjuvant chemotherapy. Some dogs tend to develop metastases within 4 months regardless of the therapy modality, while others survive for longer periods of time [17]. Similarly, despite the advance standard of care for children with OS, only 60% reach a 5-year disease free interval and 20% will not survive beyond 5 years [26].

The similarities seen in OS disease progression and survival rates in humans and dogs provides a reasonable jus-
with OS. Selection of appropriate tumor candidates based on clinicopathological relevance for gene profiling is crucial for the overall experimental design. Although advanced histological grade and postoperative chemotherapy are known confounders to influence survival and prognosis in dogs with OS [29], these factors lack to significantly influence survival in the present study population, mainly due to the small population size. Elevation of serum alkaline phosphatase is a known negative prognosticator in dogs with OS, which is true for the present study population where poor survivors had significantly higher alkaline phosphatase levels than long survivors. Some dogs, despite receiving postoperative chemotherapy, did not live beyond 6 months and can be characterized as ‘poor responders’ to chemotherapy. On the other hand, the majority of dogs that received chemotherapy within the long survivors was censored which suggests that either these tumors responded to the chemotherapy or the primary tumor did not harbor the aggressive phenotype. These data further justify distinguishing between good and poor outcome: dogs can be assessed at the gene-biological level of primary tumors regardless of post-operative chemotherapy. In addition, the current gene profiling was carried out on tumors prior to chemotherapy, where ‘clues’ at gene expression levels will help to determine which animals will probably live longer regardless of either the type of regime or decision to include postoperative chemotherapy. Figure 6). To further improve the efficacy of therapy, it is necessary to identify dogs with OS with an increased risk of treatment failure, as well as to identify those that might not need aggressive chemotherapeutic protocols.

To address issues concerning applicability for tailored therapies, microarray technologies have identified new molecular subclassifications in various human tumors, but to date there are no such reports for prognostic signatures in human and canine OS. The current research thus provides new insights into possible prognostic molecular subclassifications in canine OS. Hierarchical clustering of the differentially expressed genes revealed that long survivors have a similar gene expression profile, which is distinctly different from that of short survivors: these genes appear to be consistently downregulated among the long survivors. In contrast, clustering the genes based on expression was found to separate the short survivors into 2 subgroups. Cluster 1 genes were found to be overexpressed in subgroup B in comparison to the rest of the tumors, making this subgroup unique among the 32 tumors. Intriguingly, subgroup A appeared to have a significantly decreased survival compared to subgroup B where it shares common downregulation of genes with cluster 1. The mechanism behind this evident contradiction can only be speculated. Possibly, upregulation of both cluster 1 and cluster 2 genes provides a somewhat
protective mechanism that improves survival as compared to the combination seen for subgroup A. On the other hand, the data can also be interpreted such that Cluster 1 genes are upregulated in 25% of canine OS, where its overexpression is related to poor prognosis. Cluster 2 genes appear to be true prognostic gene signature, defining the gene expression that segregates short (<6 months) from long survivors. The importance of these findings is they provide insights into possible existence of molecular subclassifications among short survivors that may be regulated by different signaling pathways whereby, due to the complex interaction among genes, these subgroups may respond differently to certain targeted therapies. These interpretations must be addressed cautiously given the small number of samples and differentially expressed genes selected for the generation of the present dendrogram. As has been noted previously, "a replicable classification is not necessarily a useful one; but a useful one that characterizes some aspect of the population must be replicable" [30]. Therefore, insights into molecular sub-classifications among the canine OS from the present study require further validation on a larger and independent set of tumors.

Differentially expressed genes between short and long survivors: similarities with human OS

For a more biologically meaningful approach to data analysis, we looked at the level of common biological processes that differentiates short from long survivors. Genes highly expressed among short survivors of canine OS are likely to contribute to the aggressive nature of the disease in terms of increased cell cycle and proliferation, drug resistance and metastasis-associated properties. Among the transcripts that were differentially expressed between the two survival groups that have been implicated in human OS were HSP70/MOT, HSP60 and NCOR1, while HMGB1, HSP90 and MGST1 have been reported for both human and canine OS. Following discussion will focus on the relevance of these genes to human and canine OS pathogenesis and disease progression.

The main goal for discovering new therapeutic interventions for OS is to inhibit metastasis and eradicate micrometastases. The difference in growth patterns of metastases may be detected by differences in gene expression of primary tumors at the point of amputation. Due to their gene expression differences, some dogs develop
metastasis rapidly and others have delayed metastatic disease, which contributes significantly to their survival. In the overall clinical data comparison in this study, there were long survivors who did not develop metastases at all. We did not exclude these tumors from the analysis because they appear to be true survivors, where there was no metastatic disease detected after primary tumor removal. Among the differentially expressed genes between short and long survivors, CFL2, MOT and V-ATPase C have been associated with invasion and metastasis in various human tumors [31-33]. The metastatic potential of the stated genes in OS has not been reported previously; therefore additional research into their exact functions in OS metastasis is required.

### Table 4: Gene transcripts overexpressed in short survivors of canine OS found associated with 3 main biological processes

| Gene ID   | Fold change | Gene description                                                                 | Gene symbol |
|-----------|-------------|----------------------------------------------------------------------------------|-------------|
| DG2-23c15 | 3.3         | cofilin 2                                                                         | CFL2        |
| DG14-14i9 | 1.7         | Stress-70 protein, mitochondrial precursor (HSAP9) (GRP 75) (Mortalin)            | MOT         |
| DG2-72p3  | 1.6         | Vacuolar ATP synthase subunit C                                                   | V-ATPase C  |
| DG2-112n11| 2.1         | Kinesin heavy chain (Ubiquitous kinesin heavy chain)                              | UKHC        |
| DG2-123a3 | 2.0         | Microsomal glutathione S-transferase 1                                            | MGST1       |
| DG2-72p3  | 1.6         | Vacuolar ATP synthase subunit C                                                   | V-ATPase C  |
| DG2-94j4  | 1.5         | high-mobility group box 1                                                         | HMGB1       |
| DG2-23c15 | 3.3         | cofilin 2                                                                         | CFL2        |
| DG32-161c11| 2.1         | WNK lysine deficient protein kinase 1                                              | WNK1        |
| DG14-71c7 | 1.8         | serine/arginine repetitive matrix 1                                               | SRRM1       |
| DG14-14i9 | 1.7         | Stress-70 protein, mitochondrial precursor (HSAP9) (GRP 75) (Mortalin)            | MOT         |
| DG32-237k11| 1.6         | Ribosomal L1 domain containing protein 1 (PBK1 protein)                           | RSL1D1      |
| DG11-239n21| 1.6         | cell-cycle and apoptosis regulatory protein 1                                     | CCAR1       |
| DG2-106f2 | 1.4         | Translocation protein SEC63 homolog                                               | SEC63       |
| DG2-25k5  | 1.4         | SMC6 protein                                                                       | SMC6        |

The 3 processes commonly confer for the aggressive phenotype of tumor in general which include increased drug resistance, high proliferation and differentiation and high metastasis.

![Gene regulatory network generated through MetaCore's ‘shortest path analysis’ algorithm.](image)

**Figure 5**
Gene regulatory network generated through MetaCore’s ‘shortest path analysis’ algorithm.
### Table 5: Deregulated pathways in canine OS pertaining to aggressive phenotype

| Reference Study approach | Present study on canine osa poor survival associated profile 32 primary tumors | Srivastava et al., 2006 high metastatic profile human osa cell lines | Rajkumar, T. et al., 2008 drug resistant profile cell line resistant to doxorubicin | Srivastava et al., 2006 osteogenic tumor profile 10 tumors and 8 normal bones |
|--------------------------|---------------------------------------------------------------------------------|------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Samples used             | Total differential expressed genes: 1426                                      | 1999                                                             | 485                                                                         | 194                                                                         |
|                          | Total Mapped IDs on PANTHER®: 533                                                | 1185                                                             | 295                                                                         | 159                                                                         |
| Huntington disease       | ▲                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Wnt signaling pathway    | 10                                                                               | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Chemokine/cytokine       | ▲                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| signaling pathway        | ▲                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Integran signaling pathway| 7                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Parkinson disease        | 6                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Ubiquitin proteasome     | 6                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Alzheimer disease-pesenilin pathway | 5                             | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Cadherin signaling pathway| 5                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Endothelin signaling     | 5                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Glycolysis               | 5                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Heterotrimeric G-protein signaling pathway | 4 | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Angiogenesis             | 3                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Cytoskeletal regulation by Rho GTPase | 3 | ▲                                                                | ▲                                                                           | ▲                                                                           |
| EGF receptor signaling pathway | 3                             | ▲                                                                | ▲                                                                           | ▲                                                                           |
| FGF signaling pathway    | 3                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| p53 pathway              | 3                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| PDGF signaling pathway   | 3                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| T cell activation        | 3                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| TGF-beta signaling pathway| 3                                  | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Androgen/estrogen/progesterone biosynthesis | 2 | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Apoptosis signaling pathway | 2                             | ▲                                                                | ▲                                                                           | ▲                                                                           |
| B cell activation        | 2                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Hedgehog signaling       | 2                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| pathway                  | 2                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Hypoxia response via HIF activation | 2                             | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Interferon-gamma signaling pathway | 2                             | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Interleukin signaling    | 2                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| oxidative stress response | 2                             | ▲                                                                | ▲                                                                           | ▲                                                                           |
| p53 pathway feedback loops | 2                             | ▲                                                                | ▲                                                                           | ▲                                                                           |
| PI3 kinase pathway       | 2                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |
| Ras Pathway              | 2                                                                                | ▲                                                                | ▲                                                                           | ▲                                                                           |

Comparison of the top 20 pathways from 3 published human OS studies revealed 7 pathways (in bold letters) that are commonly deregulated in both human and canine OS. (▲: Common pathway hits found across different gene sets published for human OS to the present study in canine)
Over the past decade, besides metastasis, there has been growing interest in the development of multidrug resistance in OS, where various genes have been reported to contribute to the drug resistance phenotype [24,34,35]. The two drug resistance related genes overexpressed in poor survivors found in the present research in canine OS include HMGB1 and MGST1. HMGB1 expression levels have been previously investigated in 5 canine OS where its expression was suggested to be a potential marker for cisplatin therapy based clinical outcome [36]. This gene may play a role in protecting OS cells, making them less susceptible to the cisplatin where it has been similarly associated with activation of p53 [37,38] and drug resistance in other human tumors [37,39]. Similarly, MGST1 was found to be overexpressed in several human malignant tissues where it was shown to protect cells from several cytotoxic drugs [40,41] as well as by direct detoxification and downstream protection of tumor cells from oxidative stress [40]. Preliminary evidence suggests overexpression of another family member, glutathione S-transferase π, is significantly related to poor histological response to preoperative chemotherapy and poorer prognosis in human OS [41]. Similarly, an in vitro model of canine OS (COS31) with high glutathione-S-transferase activity was found to be resistant to cytotoxic effects of cisplatin [42]. Drug resistance issue is of interest in the present study population because despite given postoperative chemotherapy there were dogs unable to extend survival beyond 6 months while others received no chemotherapy and yet lived much longer. This suggests that screening through gene profiles can help with therapeutic decisions by segregating dogs based on key targets for personalized chemotherapy, and hence ensure treatment success.

Genes associated with proliferation, cell cycle and differentiation revealed at present have not been described for OS pathogenesis except for Mortalin (MOT/HSP70), HSP90 and HSP60. MOT/HSP70 has been previously shown to form complexes with p53 tumor suppressor, causing inactivation of the wild type p53 leading to exces-

---

**Figure 6**

**Classification of dogs: poor survivors (SS) and long survivors (LS).**

Over the past decade, besides metastasis, there has been growing interest in the development of multidrug resistance in OS, where various genes have been reported to contribute to the drug resistance phenotype [24,34,35]. The two drug resistance related genes overexpressed in poor survivors found in the present research in canine OS include HMGB1 and MGST1. HMGB1 expression levels have been previously investigated in 5 canine OS where its expression was suggested to be a potential marker for cisplatin therapy based clinical outcome [36]. This gene may play a role in protecting OS cells, making them less susceptible to the cisplatin where it has been similarly associated with activation of p53 [37,38] and drug resistance in other human tumors [37,39]. Similarly, MGST1 was found to be overexpressed in several human malignant tissues where it was shown to protect cells from several cytotoxic drugs [40,41] as well as by direct detoxification and downstream protection of tumor cells from oxidative stress [40]. Preliminary evidence suggests overexpression of another family member, glutathione S-transferase π, is significantly related to poor histological response to preoperative chemotherapy and poorer prognosis in human OS [41]. Similarly, an in vitro model of canine OS (COS31) with high glutathione-S-transferase activity was found to be resistant to cytotoxic effects of cisplatin [42]. Drug resistance issue is of interest in the present study population because despite given postoperative chemotherapy there were dogs unable to extend survival beyond 6 months while others received no chemotherapy and yet lived much longer. This suggests that screening through gene profiles can help with therapeutic decisions by segregating dogs based on key targets for personalized chemotherapy, and hence ensure treatment success.

Genes associated with proliferation, cell cycle and differentiation revealed at present have not been described for OS pathogenesis except for Mortalin (MOT/HSP70), HSP90 and HSP60. MOT/HSP70 has been previously shown to form complexes with p53 tumor suppressor, causing inactivation of the wild type p53 leading to exces-
HSP90 tumours from microarray analysis in previous research reported in 3 human OS cell lines as well as in 3 primary metastasis. High expressions of HSP90-beta have been impaired apoptosis and angiogenesis, invasion and multiple stages of tumorigenesis from proliferation to metastasis. Mot and HSP60, both having been strongly implicated in multiple pathways important for targeted therapies. A few pathways have been previously proposed to be of importance in either human or canine OS pathogenesis. Gene enrichment for two major pathways, namely Wnt signaling and chemokine/cytokine signaling, was found to be common among the studies conducted in human OS, and in the present study in dogs. Extensive investigations have been initiated to understand how Wnt signaling is involved in human OS pathogenesis and disease progression. Wnt signaling is not only important for cell proliferation and differentiation, but may also have possible autocrine or paracrine influence on the metastatic potential of OS [52-54]. Preliminary investigations on the roles of Wnt signaling in canine OS pathogenesis and disease progression are underway. Nevertheless, the importance of chemokine signaling has been described in canine OS where its receptor (CXCR4) was found to participate in directional migration in vitro [55]. Further research has shown that canine and human primary OS do express CXCR4, which may be involved in metastatic progression of this disease [56]. Molecular strategies targeting these 2 pathways may be beneficial for both human and dogs.

Use of microarrays for OS prognosis prediction
Clinical, histological and gene expression analysis in combination have the ability to improve the accuracy of clinical diagnostics and prognostics by precisely segregating individuals into meaningful groups, allowing for better decision making for therapeutics. However, in the past, these advanced approaches have, for most studies in human malignancies, failed to be reproduced; instead, parallel studies using distinct data sets frequently identify different gene sets as a result of variations in computational analysis methods to sample processing, array plat-
forms and research questions [57,58]. Other common barriers to reproducibility include differences in experimental design, small sample size and lack of assessment in secondary independent populations. A general problem of prognostic studies is that analyses are carried out on thousands of genes generated from small number of samples, which are often difficult to acquire from dogs where decisions to treat and follow up rely heavily on the owners. Although different human OS gene sets from different platforms and analysis techniques were identified from independent studies, they all seem to achieve agreement when it comes to pathway analysis. This insight is first described in the present study, where we performed gene-pathway enrichment analysis on distinct gene sets from several human OS studies and compared the result with our prognostic genes from the dog to reveal several common pathways conferring pathogenesis and the aggressive phenotype of OS. The conventional single biomarker discovery approach is being slowly overtaken by the idea that complex interactions among multiple genes are required to produce a disease phenotype which can be best described in terms of its deregulation of cellular signaling pathways. Preliminary studies have been initiated in an independent and larger set of canine and human OS samples to further investigate and validate the roles of the main pathways for the aggressive phenotype revealed by the present analysis.

Conclusion
The premise that gene expression profiling can be used to segregate and then identify negative and favorable prognosis cancer patients is not novel; however this is the first report of its kind in canine OS and probably in any naturally occurring cancer in the dog. The present study has revealed candidate genes that can be followed up in prospective studies as negative prognostic markers and therapeutic targets for canine OS. A molecular-based method to discriminate between short and long survivors of canine OS may be useful for future prognostic stratification of dogs at initial diagnosis, since genes associated with cell cycle/proliferation, drug resistance and metastasis are commonly overexpressed in short survivors of canine OS. In addition, we found that these survival-associated genes enrich prominent pathways such as Wnt and chemokine/cytokine signaling, which were also among the top pathways revealed by comparative pathway analysis with those of human OS gene profiling studies. These findings emphasize the excellent translational opportunity offered by canine expression studies of OS pathogenesis and disease progression that can be used for future therapeutic and prognostic strategies. Other approaches, such as protein profiling as well as in vitro studies, will be necessary to elucidate further the biological significance of these findings.

Methods
Patient and tumor data
Thirty-two histological confirmed canine OS, with available survival data, that were presented at the University Clinic for Companion Animals in Utrecht The Netherlands from 1996 - 2003 were selected in this study. These dogs were not subjected to any sort of therapy prior to harvesting of the tumor tissue. Tumor samples were harvested under sterile conditions during surgery (amputation/marginal resection/total resection). Samples were snap-frozen in liquid nitrogen and stored in sterile tubes at -70°C. An adjacent tumor specimen was fixed in 4% neutral buffered formalin, decalcified in 10% EDTA and embedded in paraffin. Four μm tissue sections were stained with hematoxylin and eosin where the diagnosis and histological grading was carried out by a board certified veterinary pathologist [59]. Various clinical and pathological parameters were evaluated retrospectively for the dogs included in this study.

Statistical and survival analysis
All 32 dogs in this study were followed up from the time of diagnosis until death, for up to a period of 5 years. Survival time (ST) was recorded for all dogs. ST was defined as the time period from initial diagnosis until death. Patients were censored if they died due to causes other than metastatic disease. The Kaplan-Meier method was used to draw disease free interval survival curves. Tests for comparison of groups of survival data were made using the Mantel-Cox log rank test (SPSS version 15.0). Univariate Cox proportional hazard analysis was conducted on the overall population of 32 dogs with and without stratification for chemotherapy. Variables found by univariate analysis to influence survival at a cut off of P < 0.15 were further subjected to multivariate analysis using the Cox proportional hazard regression model (backward elimination using Newton Raphson algorithm) to determine whether the variables could independently influence survival in the whole and/or subpopulation of dogs in the present study. Hazard ratios (HR) and confidence intervals (CI) were calculated and reported using EGRET for Windows Version 2.013 (Cytel Software Corporation, Cambridge, MA, USA). Further analyses on discrete variables comparing the subpopulation of dogs were performed using the Fisher’s exact test on SPSS version 15.0. Statistical significance was defined as P < 0.05.

RNA isolation and amplification
Bone tumor samples were pulverized for 45 seconds at a speed of 2000 rounds per minute in the Mikro Dismembrator® U (B. Braun Biotech International, Melsungen, Germany) in ribonuclease free plastic containers. The procedure was repeated if samples were too big. Cooling in liquid nitrogen between cycles was performed. Bone tumor powder was stored in sterile tubes at -70°C. Total
RNA isolation and purification was carried out with 600 mU/ml Proteinase K as an additional pretreatment step using the RNeasy mini kit (Qiagen, The Netherlands) following the manufacturer's protocol. The RNA samples were treated with DNase-I (Qiagen RNase-free DNase kit). Total RNA was quantified using the NanoDrop® spectrophotometer (NanoDrop Technologies). cRNA synthesis was performed using the protocol described. Quality of total and amplified cRNA was analyzed using a bioanalyzer (Agilent Technologies, The Netherlands).

**Microarray hybridization and data normalization**

Thirty-two tumors were sorted into two prognosis groups based on survival time (ST). They were defined as short-term survivors (SS; 16 dogs with a negative prognosis that survived less than 6 months) and long-term survivors (LS; 16 dogs with better prognosis that survived 6 months or longer). Microarray hybridization, scanning and image analysis were conducted according to the protocol described [60]. A common reference cRNA pool consisting of all 32 tumors was used to hybridize against each tumor on the array. Dyes were swapped as described in previous literatures [61], where equal numbers of samples within each tumor group were subjected to dye swap to avoid dye bias effect. Defective spots were flagged and normalization was carried out using the Lowess print-tip normalization technique. Log transformation was applied to the microarray raw data after normalization and data from dye swap arrays were switched before they were subjected for further statistical analysis. The microarray data files were deposited in the public database (GEO: GSE14033).

**Microarray data analysis**

Microarray data analysis and calculations were performed using a two class unpaired approach to compare the normalized and log-transformed expression data between the two groups. Calculations were done using Significance Analysis of Microarray (SAM) (Stanford University, CA, USA) [62], using 100 permutations to the k-nearest neighbor with 10 neighbors and newly initialized random seeds for each analysis. The gene list for this analysis was generated at a false discovery rate (FDR) of 10%. Genes with fold changes of 1.4 and above were selected for further analyses [63]. Hierarchical clustering of genes that were differentially regulated between the two groups of tumors was performed. A two-dimensional dendrogram of both gene tree and condition tree based on standard correlation was generated using the GeneSpring® (Agilent Technologies, The Netherlands) software [64]. The Gene Ontology (GO) database was used to cross check the gene molecular and biological functions [http://www.ncbi.nlm.nih.gov].

**Quantitative real-time PCR**

Total tumor RNA was isolated using the protocol mentioned above. Synthesis of cDNA was carried out from 1.0 μg total RNA in 40 μl reaction volumes using the iScript™ cDNA synthesis kit as described by the manufacturer's protocol (Bio-Rad, The Netherlands). Quantitative real-time PCR (Q-PCR) was performed on four candidate genes from the list of differential expressed genes, as well as the ribosomal protein S19 (RPS19) and hypoxanthine phosphoribosyl transferase (HPRT) as endogenous reference gene for normalizations. Primer sets (Table 6) were designed using the software Primer 3 [65]. Q-PCR was carried out using the SYBR® green fluorescent dye method, which was further analyzed by the Bio-Rad MyIQ software (BioRad, The Netherlands). The Q-PCR products were sequenced to verify the specificity of the primer sets. Data was analyzed on REST-XL (pair wise fixed reallocation and randomization test) software [66] that estimates a relative

### Table 6: Primers used for quantitative real-time PCR

| Gene symbol | Forward and Reverse Primers | Temp (°C) |
|-------------|-----------------------------|----------|
| ANKR17      | FW: 5’-AAGTAGGCGACCACCCCTGAC-3’  
             RW: 5’-CTAGAGCGCAAAATGTTGGCA-3’ | 60.0     |
| MRPS31      | FW: 5’-GAATTGGCTCTGCTTGGAG-3’  
             RW: 5’-ATCCAGTGGACGAAGATGG-3’ | 60.0     |
| NCOR1       | FW: 5’-TCTTCTCTGCTTGTCAG-3’  
             RW: 5’-GCATCCCAAAAACCTTTGGA-3’ | 59.6     |
| MGST1       | FW: 5’-CGGACACATGATAGGGG-3’  
             RW: 5’-GATTGGCTGGAAAAG-3’ | 62.0     |
| RPS19       | FW: 5’-CCCTCTCAAAAGCTTGGGG-3’  
             RW: 5’-GTTCTCATCGTGGGAGCAAG-3’ | 61.0     |
| HPRT        | FW: 5’-AGCCTGCTGGTAAAGGAC-3’  
             RW: 5’-TTATAGTCAAGGCA-3’ | 56.0     |
normalized fold change of gene expression between the two groups which is then compared to the microarray fold change data.

**Pathway analyses**
Analysis of gene regulatory networks present among the differentially expressed genes identified by SAM was performed using the 'Shortest Path Analysis' algorithm of MetaCore™ Analytical Suite (GeneGo Inc., St. Joseph, MI, USA) [67]. In addition, for further insight into overall pathway discovery, we applied a less stringent rule where correction for multiple testing method was not applied in obtaining differential expressed genes [68]. EDGE (Extraction of Differential Gene Expression) software [http://faculty.washington.edu/jstorey/edge] was used to generate the genes differentially expressed between the short and long survivors of canine OS at a cutoff threshold of \( P < 0.05 \) [69]. The differential expressed genes identified by EDGE from the present study in canine were compared with the human homologues to obtain a list of gene symbols or human RefSeq ID that was later subjected for pathway analysis using the program PANTHER® (Protein ANAlysis THrough Evolutionary Relationships) [http://www.pantherdb.org/][60,68]. Pathways revealed by this analysis were sorted according to number of gene hits and compared with the top 20 pathways from various human OS microarray studies.

**Abbreviations**
SS: short survivors; LS: long survivors; ST: overall survival time; DFI: disease free interval; FDR: false discovery rate; SAM: Significance Analysis of Microarray; GEO: Gene Expression Omnibus; QPCR: Quantitative Real Time PCR; CI: Confidence Interval

**Competing interests**
The authors declare that they have no competing interests.

**Authors’ contributions**
GTS analyzed the clinicopathological and microarray data, performed statistical analyses, designed primers, carried out QPCR, pathway analyses, drafted the manuscript and revised the manuscript according to the reviewers’ recommendations. MEW helped with RNA amplification, microarray hybridizations and contributed in the research discussions. IAM helped with assisted in coordination of work, data interpretation, pathway analyses and final manuscript revision. JK participated in the experimental design, set up of the initial study, carried out the overall responsibility of the research performed and revised the manuscript critically. NASR assisted with the bioinformatics aspect of microarray analysis, contributed in research discussions and reviewed the manuscript critically. HF assisted in sample collection, retrieval of survival data and performed RNA isolation. All authors have reviewed and approved the final and revised manuscript.

**Additional material**

**Additional file 1**
Univariate analysis. a) Univariate analysis of specific variable influences on survival time (ST) among dogs from the entire population of study. b) Variables with \( P < 0.15 \) from univariate analysis that were subsequently forced into multivariate model identifies elevation of serum alkaline phosphatase with significantly increased HR for a shorter ST. § Missing data, * Category which was used as baseline reference, ‡ Continuous variables
[Click here for file](http://www.biomedcentral.com/content/supplementary/1476-4598-8-72-S1.doc)

**Additional file 2**
Cox proportional hazard analysis upon stratification for postoperative chemotherapy. Cox proportional hazard analysis (univariate) upon stratification for postoperative chemotherapy revealed no significant influence of the variables assessed on survival time of the dogs in the total population of study (\( n = 32 \)).
[Click here for file](http://www.biomedcentral.com/content/supplementary/1476-4598-8-72-S2.doc)

**Additional file 3**
Fisher’s exact test and univariate Cox proportional hazard analysis carried out on the new subgroups. Both subgroups did not differ in frequency distribution of the variables assessed and none of the variables assessed were found to significantly influence survival. NA, non applicable; HR, hazard ratio
[Click here for file](http://www.biomedcentral.com/content/supplementary/1476-4598-8-72-S3.doc)

**Additional file 4**
Differential expressed genes categorized based on their molecular functions
[Click here for file](http://www.biomedcentral.com/content/supplementary/1476-4598-8-72-S4.doc)

**Acknowledgements**
The authors are grateful to the Ministry of Higher Education (MOHE) of (Malaysia) and University Putra Malaysia for providing financial support for the PhD candidate working on this project. The statistical advice by Dr. Erik Teske, graphical assistance by I.C.M. Lavrijsen and QPCR assistance by Frank Riemers is greatly appreciated. We thank Ms Linda McPhee [http://www.write-research.com] for her contribution in preparation of the manuscript.

**References**
1. Lindblad-Toh K, Wade CM, Mikkelson TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulpokas EJ, Zody MC, 3rd, Maucci E, Xie X, Breen M, Wayne RK, Ostrander EA, Ponting CP, Galibert F, Smith DR, Delong PJ, Kirkness E, Alvarez P, Biagi T, Brockman W, Butler J, Chin CW, Cook A, Cuff J, Daly MJ, DeCaprio D, Gnerre S, et al.: Genome sequence, comparative analysis and haplotype structure of the domestic dog. *Nature* 2005, 438:803-819.
2. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, Niemi S, Comstock KE, Ostrander E, Westmoreland S, Withrow S: The dog as a cancer model. *Nat Biotechnol* 2006, 24:1065-1066.
3. Brodey RS, Riser WH: Canine osteosarcoma. A clinicopathological study of 194 cases. Clin Orthop Relat Res 1969, 62:54-64.

4. Tjalma WA: Canine osteosarcoma: estimation of relative risk as a function of body size. J Natl Cancer Inst 1966, 36:1137-1150.

5. Dickerson ME, Page RL, LaDue TA, Hauck ML, Thrall DE, Stebbins ME, Price GS: Retrospective analysis of axial skeleton osteosarcoma in 22 large-breed dogs. J Vet Intern Med 2001, 15:10-24.

6. Dornman SK, Hurvitz AJ, Patnaik AK: Primary and secondary bone tumors in the dog. J Small Anim Pract 1977, 18:313-326.

7. Brodey RS: The use of naturally occurring cancer in domestic animals for research into human cancer: general considerations and a review of canine skeletal osteosarcoma. Yale J Biol Med 1989, 62:91-102.

8. Pirkey-Ehrhart N, Withrow SJ, Straw RC, Ehrhart EJ, Page RL, Hottinger HL, Hahn KA, Morrison WB, Albrecht MR, Hedlund CS, Hammer AS, Holmberg DL, Moore AS, King RA, Klauenser JS: Primary rib tumors in 54 dogs. J Am Anim Hosp Assoc 1995, 31:65-69.

9. Withrow SJ: Immunohistochemical expression of doxorubicin for treatment of canine and feline osteogenic sarcoma. Eur J Cancer 1978, 14:287-293.

10. La Rue SM, Withrow SJ: Tumors of the skeletal system. In Clinical Veterinary Oncology Edited by: Withrow SJ, MacEwen G. Philadelphia: WB Saunders; 1998:1899-1902.

11. Ling GV, Morgan JP, Pool RR: Primary bone tumors in the dog: a combined clinical, radiographic, and histologic approach to early diagnosis. J Am Vet Med Assoc 1974, 165:55-67.

12. Brodey RS, Abt DA: Results of surgical treatment in 65 dogs with osteosarcoma. J Am Vet Med Assoc 1976, 168:1032-1035.

13. Kirpenstein J, Teske E, Kilk M, Klaener T, Rutteman GR: Lobaplatin as an adjuvant chemotherapy to surgery in canine appendicular osteosarcoma: a phase II evaluation. Anticancer Res 2002, 22:2765-2770.

14. Brodey RS, Ehrhart NP, Rennell WS, Lafferty M, Withrow SJ: Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999-2006). J Am Vet Med Assoc 2008, 232:1504-1510.

15. Chua-Tuan JL, Kebir Y, Attaya AS: Evaluation of ciseplatin for treatment of appendicular osteosarcoma in dogs. J Vet Med Sci 1988, 50:507-511.

16. Spodnick GJ, Berg J, Rand WM, Schelling SH, Couto G, Harvey HJ, Henderson RA, MacEwen G, Mauldin N, McCaw DL, Moore AS, Morrison WB, Norris AM, OBradovich J, OKeefe DA, Page RL, Ruslander D, Klausner JS, Straw RC, Thompson JP, Withrow SJ: Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 1992, 191:949-952.

17. Kraegel SA, Madewell BR, Simonson E, Gregory CR: Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). J Am Vet Med Assoc 1991, 199:1057-1059.

18. Kirpenstein J, Timmermans-Spring EP, van Garderen E, Rutteman GR, van den Bogaert U, Leeuwen IS, Mol JA: Growth hormone gene expression in canine normal growth plates and spontaneous osteosarcoma. Mol Cell Endocrinol 2002, 197:179-185.

19. Yang R, Haung BH, Kubo T, Kawano H, Chau A, Sowers R, Huvos AG, Meyers PA, Healey JH, Gorlick R: Over-expression of parathyroid hormone type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 2007, 121:943-954.

20. Wolf M, El-Rifai W, Tarkkanen M, Kononen J, Serra M, Eriksen EF, Maitland NJ, Rigas B, Stephen DA: An expression signature classifies chemotherapeutic-resistant pediatric osteosarcoma. Cancer Res 2005, 65:1748-1754.

21. Rajkumar T, Yamuna M: Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. Anticancer Res 2003, 23:4055-4065.

22. Srivastava A, Fuchs B, Zhang K, Ruan M, Halder C, Mahmum E, Weber K, Bolander ME, Sarkar G: High WT1 expression is associated with very poor survival of patients with osteosarcomic metastasis. Clin Cancer Res 2006, 12:4237-4243.

23. Beldicek S, Kemp-Bielack B, Dellong G, Exner GU, Flige S, Helmike K, Kozt R, Salzer-Kuntschik M, Werner M, Winklmann W, Zoubek A, Jurgens H, Winkler K: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma chemotherapy study group protocols. J Clin Oncol 2002, 20:776-780.

24. Withrow SJ, Powers BE, Straw RC, Wilkins RM: Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop Relat Res 1991, 159-168.

25. MacEwen EG: Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990, 9:125-136.

26. Loukopoulos P, Robinson WF: Clinicopathological relevance of tumour grading in canine osteosarcoma. J Comp Pathol 2007, 136:65-73.

27. Gansner NR, Page GP, Sprague AP, Gorman BS, Allison DB: Reproducible clusters from microarray research: whither? BMC Bioinformatics 2005, 6(Suppl 2):S10.

28. Sennour SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya AM, Martinez-Zaguilan R, Yacuollar H+ATPas in human breast cancer cells with distinct metastatic potential: distribution and functional activity. J Physiol Cell Physiol 2004, 286:C1443-C1452.

29. Wang W, Eddy R, Condeelis J: The collin I pathway in breast cancer invasion and metastasis. Nat Rev Cancer 2007, 7:29-40.

30. Dandans SR, Lawrie LC, Rooney PH, Murray GI: Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 2005, 207:74-81.

31. Walters DK, Steinnmann P, Langsmang B, Schmutz S, Born W, Fuchs B: Identification of potential chemoresponse genes in osteosarcoma metastasis. Cancer Res 2004, 64:5245-5255.

32. Chau AJ, Gorlick R: Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006, 6:1075-1085.

33. Meyer B, Murua Escobar H, Haucke S, Richter A, Winkler S, Rogalla P, Flahor AM, Bullerdiek J, Nolte I: Expression pattern of the HMGB1 gene in sarcomas of the dog. Anticancer Res 2004, 24:707-710.

34. Imamura T, Izumi H, Nagatani G, Ise T, Nomoto M, Iwamoto Y, Kondoh K: Interaction of pepsinogen and pepsin: enhanced in vitro reversal of cisplatin-modified DNA by high mobility group I protein. J Bio Chem 2001, 276:7534-7540.

35. Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M, Prives C: Novel findings in gene expression detected in human osteosarcoma by DNA microarray. Cancer Gene Ther 2000, 7:128-132.

36. Krynetskaia N, Xie H, Vucetic S, Obradovic Z, Krynetsky E: High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs. Mol Pharmacol 2008, 73:260-269.

37. Johansson K, Ahlen K, Rinaldi R, Sahlander K, Siritantikorn A, Mortensten R: Microsomal glutathione transferase 1 in anticancer drug resistance. Carcinogenesis 2007, 28:465-470.

38. Uozaki H, Horouchi I, Ishida T, Iijima T, Imamura T, Machinami R: Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 1997, 79:2336-2344.

39. Shoieb AM, Hahn KA, Van Laack RL, Barnhill MA: In vitro reversal of glutathione-S-transferase mediated resistance in canine osteosarcoma (COS31) cells. In Vivo 1998, 12:455-462.

40. Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R: Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J Biol Chem 2005, 280:39373-39379.

41. Kaul Z, Yaguchi T, Kaur K, Wadhwa R: Quantum dot-based protein imaging and functional significance of two mitochondrial chaperones in cellular senescence and carcinogenesis. Ann N Y Acad Sci 2006, 1067:465-473.

42. Uozaki H, Ishida T, Kakeshi C, Horouchi I, Gotoh T, Iijima T, Imamura T, Machinami R: Expression of heat shock proteins in osteo-

http://www.molecular-cancer.com/content/8/1/72

Page 17 of 18 (page number not for citation purposes)
osarcoma and its relationship to prognosis. Pathol Res Pract 2000, 196:665-673.

46. Treibs K, Grabert R, Windhager R, Grohs JG, Holzer G, Berger P, Kotz R: Serum antibodies against the heat shock protein 60 are elevated in patients with osteosarcoma. Immunobiology 2000, 201:368-376.

47. McCleese JK, Bear MD, Fossey SL, Mihaelak FM, Foley KP, Ying W, Barsoum J, London CA: The novel HSPer inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer 2009 in press.

48. Yan T, Wunder JS, Gokgoz N, Gill M, Eskandarian S, Parkes RK, Bull SB, Bell RS, Andrusill LS: COP53 amplification and clinical outcome in osteosarcoma. Cancer 2007, 109:1870-1876.

49. Zhang J, Chen X, Kent MS, Rodriguez CO, Chen X: Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor. Mol Cancer Res 2009, 7:67-78.

50. Mendoza S, Konishi T, Dernell WS, Withrow SJ, Miller CW: Status of the p53, Rb and MDM2 genes in canine osteosarcoma. Anti-cancer Res 1998, 18:4449-4453.

51. Kirpenstein J, Kik M, Teske E, Ruttemann GR: TP53 gene mutations in canine osteosarcoma. Vet Surg 2008, 37:454-460.

52. Chen K, Fallen S, Abass AO, Hayran M, Gonzalez C, Wodajo F, MacDonald T, Toretsky JA, Uren A: Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer 2008, 51:349-355.

53. Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza B, Meyers PA, Gorlick R: Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004, 64:2734-2739.

54. Hoang BH, Kubo T, Healey JH, Sowers R, Mazza B, Yang R, Huvos AG, Meyers PA, Gorlick R: Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004, 109:106-111.

55. Fan TM, Barger AM, Fredrickson RL, Fitzsimmons D, Garrett LD: Investigating CXCR4 expression in canine appendicular osteosarcoma. J Vet Intern Med 2008, 22:602-608.

56. Tusher VG, Tibshirani R, Chu G: Significance analysis of micro-arrays applied to the/ionizing radiation response. Proc Nat Acad Sci USA 2001, 98:5116-5121.

57. van’t Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.

58. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

59. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

60. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

61. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

62. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

63. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

64. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

65. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

66. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

67. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

68. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

69. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

70. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

71. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

72. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

73. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

74. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

75. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.

76. van’t Veer LJ, Dai H, van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.